Ezobresib

Ezobresib

Clinical data
Other names	BMS-986158
Identifiers
IUPAC name 2-[3-(3,5-dimethyltriazol-4-yl)-5-[(S)-oxan-4-yl(phenyl)methyl]pyrido[3,2-b]indol-7-yl]propan-2-ol
CAS Number	1800340-40-2
PubChem CID	118196485
DrugBank	DB15435
ChemSpider	58828664
UNII	X8BW0MQ5PI
KEGG	D12710
ChEMBL	ChEMBL4297458
Chemical and physical data
Formula	C30H33N5O2
Molar mass	495.627 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=C(N(N=N1)C)C2=CC3=C(C4=C(N3[C@@H](C5CCOCC5)C6=CC=CC=C6)C=C(C=C4)C(C)(C)O)N=C2
InChI InChI=InChI=1S/C30H33N5O2/c1-19-28(34(4)33-32-19)22-16-26-27(31-18-22)24-11-10-23(30(2,3)36)17-25(24)35(26)29(20-8-6-5-7-9-20)21-12-14-37-15-13-21/h5-11,16-18,21,29,36H,12-15H2,1-4H3/t29-/m1/s1 Key:KGERZPVQIRYWRK-GDLZYMKVSA-N

Ezobresib is an investigational new drug that has been evaluated for the treatment of cancer. It inhibits Bromodomain and Extra-Terminal domain (BET) proteins, with potential antineoplastic activity. Developed by Bristol Myers Squibb, this therapeutic agent has been studied for its efficacy in treating various cancers, including solid tumors and hematological malignancies. Despite showing promise in early-phase clinical trials, recent developments suggest that Bristol Myers Squibb has decided to discontinue further development of ezobresib.